Cargando…

Is 3-Tesla Gd-EOB-DTPA-Enhanced MRI with Diffusion-Weighted Imaging Superior to 64-Slice Contrast-Enhanced CT for the Diagnosis of Hepatocellular Carcinoma?

OBJECTIVES: To compare 64-slice contrast-enhanced computed tomography (CT) with 3-Tesla magnetic resonance imaging (MRI) using Gd-EOB-DTPA for the diagnosis of hepatocellular carcinoma (HCC) and evaluate the utility of diffusion-weighted imaging (DWI) in this setting. METHODS: 3-phase-liver-CT was p...

Descripción completa

Detalles Bibliográficos
Autores principales: Maiwald, Bettina, Lobsien, Donald, Kahn, Thomas, Stumpp, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223069/
https://www.ncbi.nlm.nih.gov/pubmed/25375778
http://dx.doi.org/10.1371/journal.pone.0111935
_version_ 1782343159629479936
author Maiwald, Bettina
Lobsien, Donald
Kahn, Thomas
Stumpp, Patrick
author_facet Maiwald, Bettina
Lobsien, Donald
Kahn, Thomas
Stumpp, Patrick
author_sort Maiwald, Bettina
collection PubMed
description OBJECTIVES: To compare 64-slice contrast-enhanced computed tomography (CT) with 3-Tesla magnetic resonance imaging (MRI) using Gd-EOB-DTPA for the diagnosis of hepatocellular carcinoma (HCC) and evaluate the utility of diffusion-weighted imaging (DWI) in this setting. METHODS: 3-phase-liver-CT was performed in fifty patients (42 male, 8 female) with suspected or proven HCC. The patients were subjected to a 3-Tesla-MRI-examination with Gd-EOB-DTPA and diffusion weighted imaging (DWI) at b-values of 0, 50 and 400 s/mm(2). The apparent diffusion coefficient (ADC)-value was determined for each lesion detected in DWI. The histopathological report after resection or biopsy of a lesion served as the gold standard, and a surrogate of follow-up or complementary imaging techniques in combination with clinical and paraclinical parameters was used in unresected lesions. Diagnostic accuracy, sensitivity, specificity, and positive and negative predictive values were evaluated for each technique. RESULTS: MRI detected slightly more lesions that were considered suspicious for HCC per patient compared to CT (2.7 versus 2.3, respectively). ADC-measurements in HCC showed notably heterogeneous values with a median of 1.2±0.5×10(−3) mm(2)/s (range from 0.07±0.1 to 3.0±0.1×10(−3) mm(2)/s). MRI showed similar diagnostic accuracy, sensitivity, and positive and negative predictive values compared to CT (AUC 0.837, sensitivity 92%, PPV 80% and NPV 90% for MRI vs. AUC 0.798, sensitivity 85%, PPV 79% and NPV 82% for CT; not significant). Specificity was 75% for both techniques. CONCLUSIONS: Our study did not show a statistically significant difference in detection in detection of HCC between MRI and CT. Gd-EOB-DTPA-enhanced MRI tended to detect more lesions per patient compared to contrast-enhanced CT; therefore, we would recommend this modality as the first-choice imaging method for the detection of HCC and therapeutic decisions. However, contrast-enhanced CT was not inferior in our study, so that it can be a useful image modality for follow-up examinations.
format Online
Article
Text
id pubmed-4223069
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-42230692014-11-13 Is 3-Tesla Gd-EOB-DTPA-Enhanced MRI with Diffusion-Weighted Imaging Superior to 64-Slice Contrast-Enhanced CT for the Diagnosis of Hepatocellular Carcinoma? Maiwald, Bettina Lobsien, Donald Kahn, Thomas Stumpp, Patrick PLoS One Research Article OBJECTIVES: To compare 64-slice contrast-enhanced computed tomography (CT) with 3-Tesla magnetic resonance imaging (MRI) using Gd-EOB-DTPA for the diagnosis of hepatocellular carcinoma (HCC) and evaluate the utility of diffusion-weighted imaging (DWI) in this setting. METHODS: 3-phase-liver-CT was performed in fifty patients (42 male, 8 female) with suspected or proven HCC. The patients were subjected to a 3-Tesla-MRI-examination with Gd-EOB-DTPA and diffusion weighted imaging (DWI) at b-values of 0, 50 and 400 s/mm(2). The apparent diffusion coefficient (ADC)-value was determined for each lesion detected in DWI. The histopathological report after resection or biopsy of a lesion served as the gold standard, and a surrogate of follow-up or complementary imaging techniques in combination with clinical and paraclinical parameters was used in unresected lesions. Diagnostic accuracy, sensitivity, specificity, and positive and negative predictive values were evaluated for each technique. RESULTS: MRI detected slightly more lesions that were considered suspicious for HCC per patient compared to CT (2.7 versus 2.3, respectively). ADC-measurements in HCC showed notably heterogeneous values with a median of 1.2±0.5×10(−3) mm(2)/s (range from 0.07±0.1 to 3.0±0.1×10(−3) mm(2)/s). MRI showed similar diagnostic accuracy, sensitivity, and positive and negative predictive values compared to CT (AUC 0.837, sensitivity 92%, PPV 80% and NPV 90% for MRI vs. AUC 0.798, sensitivity 85%, PPV 79% and NPV 82% for CT; not significant). Specificity was 75% for both techniques. CONCLUSIONS: Our study did not show a statistically significant difference in detection in detection of HCC between MRI and CT. Gd-EOB-DTPA-enhanced MRI tended to detect more lesions per patient compared to contrast-enhanced CT; therefore, we would recommend this modality as the first-choice imaging method for the detection of HCC and therapeutic decisions. However, contrast-enhanced CT was not inferior in our study, so that it can be a useful image modality for follow-up examinations. Public Library of Science 2014-11-06 /pmc/articles/PMC4223069/ /pubmed/25375778 http://dx.doi.org/10.1371/journal.pone.0111935 Text en © 2014 Maiwald et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Maiwald, Bettina
Lobsien, Donald
Kahn, Thomas
Stumpp, Patrick
Is 3-Tesla Gd-EOB-DTPA-Enhanced MRI with Diffusion-Weighted Imaging Superior to 64-Slice Contrast-Enhanced CT for the Diagnosis of Hepatocellular Carcinoma?
title Is 3-Tesla Gd-EOB-DTPA-Enhanced MRI with Diffusion-Weighted Imaging Superior to 64-Slice Contrast-Enhanced CT for the Diagnosis of Hepatocellular Carcinoma?
title_full Is 3-Tesla Gd-EOB-DTPA-Enhanced MRI with Diffusion-Weighted Imaging Superior to 64-Slice Contrast-Enhanced CT for the Diagnosis of Hepatocellular Carcinoma?
title_fullStr Is 3-Tesla Gd-EOB-DTPA-Enhanced MRI with Diffusion-Weighted Imaging Superior to 64-Slice Contrast-Enhanced CT for the Diagnosis of Hepatocellular Carcinoma?
title_full_unstemmed Is 3-Tesla Gd-EOB-DTPA-Enhanced MRI with Diffusion-Weighted Imaging Superior to 64-Slice Contrast-Enhanced CT for the Diagnosis of Hepatocellular Carcinoma?
title_short Is 3-Tesla Gd-EOB-DTPA-Enhanced MRI with Diffusion-Weighted Imaging Superior to 64-Slice Contrast-Enhanced CT for the Diagnosis of Hepatocellular Carcinoma?
title_sort is 3-tesla gd-eob-dtpa-enhanced mri with diffusion-weighted imaging superior to 64-slice contrast-enhanced ct for the diagnosis of hepatocellular carcinoma?
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223069/
https://www.ncbi.nlm.nih.gov/pubmed/25375778
http://dx.doi.org/10.1371/journal.pone.0111935
work_keys_str_mv AT maiwaldbettina is3teslagdeobdtpaenhancedmriwithdiffusionweightedimagingsuperiorto64slicecontrastenhancedctforthediagnosisofhepatocellularcarcinoma
AT lobsiendonald is3teslagdeobdtpaenhancedmriwithdiffusionweightedimagingsuperiorto64slicecontrastenhancedctforthediagnosisofhepatocellularcarcinoma
AT kahnthomas is3teslagdeobdtpaenhancedmriwithdiffusionweightedimagingsuperiorto64slicecontrastenhancedctforthediagnosisofhepatocellularcarcinoma
AT stumpppatrick is3teslagdeobdtpaenhancedmriwithdiffusionweightedimagingsuperiorto64slicecontrastenhancedctforthediagnosisofhepatocellularcarcinoma